| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Molecular mechanisms of plastic changes of pancreatic β cells, liver, adipose tissue under and after insulin resistance were analyzed using insulin receptor IGF-1 receptor blocker, OSI-906 administration model.
OSI-906 administration showed pancreatic β-cell proliferation independent of insulin/IGF-1, significant atrophy of visceral fat, and fatty liver. These differences were not shown after withdrawal of OSI-906. In this model, administration of leptin, a drug for lipoatrophic diabetes, and DPP-4 inhibitor, an oral diabetes agent, improved fatty liver, and administration of SGLT-2 inhibitor, an oral diabetes agent, improved glucose tolerance. These results suggested that these agents have organ-specific effect independent of insulin/IGF-1.
|
